The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Brought to you by Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View aml content recommended for you

Pan-IDH inhibitors

IDH family members belong to group of enzymes which catalyze metabolic reactions and epigenetic modifications. Mutations in IDH1 and IDH2 generate an oncometabolite product, 2-hydroxyglutarate (2HG), which has been shown to interfere with metabolic and epigenetic mechanisms responsible for cellular differentiation and apoptosis. Pan-IDH inhibitors have inhibitory effects to IDH1 and IDH2 mutations. AG-881 is an example of a pan-IDH inhibitor in development for AML.